Factor IX as Adjunctive Therapy to Emicizumab (EMIX)

Summary

This trial will enroll patients with severe hemophilia A. Experiments will be run in vitro by spiking patients' blood with different molecules (currently used and theoretically proposed as adjunctive therapy to emicizumab), therefore no more than minimal direct risk to patients is expected. This is a pilot preclinical study.

Timeline

Start

2022-08-01

Primary completion

2024-03-07

Completion

2024-07-14

Drugs

Indications